A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Sponsored by Helixmith Co., Ltd.
About this trial
Last updated 3 years ago
Study ID
VMDN-003-2b
Status
Recruiting
Type
Interventional
Phase
Phase 3
Placebo
Yes
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended a year ago
What is this trial about?
To evaluate the durability of efficacy and long-term safety of intramuscular (IM)
administration of Engensis or Placebo that was administered in the double-blind, randomized,
VMDN-003-2 Placebo-controlled Phase 3 Study.
What are the participation requirements?
Inclusion Criteria
- Completed study VMDN-003-2 and consent to enroll in study VMDN-003-2b
Exclusion Criteria
- None
Locations
Location
Status
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting